Reference number(s)
532-A

Initial Prior Authorization
Multaq

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Multaq	dronedarone

Indications

FDA-Approved Indications

Multaq is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF).

Coverage Criteria

Atrial Fibrillation (AF)

Authorization may be granted when the requested drug is being prescribed to reduce the risk of hospitalization for atrial fibrillation (AF) in a patient with a history of paroxysmal or persistent AF, i.e., non-permanent AF.

Reference number(s)
532-A

Duration of Approval (DOA)

- 532-A: DOA: 12 months

References

1. Multaq [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; May 2024.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. https://online.lexi.com. Accessed April 18, 2025.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 04/18/2025).